-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On November 2, Kangfang Biological announced that the new tumor immunotherapy drug AK112 (PD-1/VEGF bispecific antibody) was approved by CDE, and the development of single-drug or combined chemotherapy neoadjuvant/adjuvant therapy can cut non-small cell lung cancer (NSCLC).
) Phase II clinical study
.
AK112 is the world's first bispecific antibody drug to enter Phase III clinical research
The study is an open, multi-center, randomized phase II clinical trial, which aims to evaluate whether AK112 monotherapy or combined chemotherapy neoadjuvant/adjuvant therapy can improve the pathological remission rate of surgery for patients with resectable NSCLC
.
AK112 is a PD-1/VEGF double antibody designed based on Kangfang's TETRABODY technology.
It can block the binding of PD-1 to PD-L1, PD-L2, and the binding of VEGF to VEGF receptors
.
The combination therapy of PD-1 antibody and VEGF blocker has shown strong curative effect in a variety of tumor types (such as renal cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma)
Lung cancer is one of the cancers with the highest morbidity and mortality in the world, of which about 85% are NSCLC, and about 30% of patients are resectable early and mid-term NSCLC at first diagnosis
.
A number of clinical studies have shown that neoadjuvant immunotherapy can play an important role in the comprehensive treatment of early NSCLC, with controllable adverse reactions and less delay in surgery
